Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NPRO: Extraordinary general meeting completed

Reference is made to the stock exchange notice on 16 August 2021, regarding the compulsory acquisition of all shares in Norwegian Property ASA ("Norwegian Property") not already owned by Geveran Trading Co. Limited. Following the compulsory acquisition, Norwegian Property has today, 20 August 2021, held an extraordinary general meeting. All resolutions were unanimously approved, including, inter alia, the resolution to apply for delisting of the shares in Norwegian Property from the Oslo Stock Exchange. Accordingly, Norwegian Property will apply for a delisting of its shares from the

Arctic Bioscience AS: Invitation to Presentation of H1 2021 Results

Arctic Bioscience AS will publish its financial results for the first half of 2021 onThursday August 26, 2021, at 07:00 CEST. The company will host a webcastpresentation of the results the same day at 08:30 CEST.Arctic Bioscience AS H1 2021 webcast presentation:Date: Thursday August 26, 2021Time: 08:30 a.m. CESTFormat: Webcast and Q&ALanguage: EnglishLink: https://streams.eventcdn.net/arcticbioscienceas/financial-results-first-half-2021/registerThe H1 2021 report and presentation will be made available at www.arctic-bioscience.comand on the Euronext Growth company page (

Norway Royal Salmon ASA (NRS): SalMar intends to launch a voluntary cash offer to acquire all outstanding shares in Norway Royal Salmon

This is a copy of the stock exchange announcement from Salmar ASA at 08:50 today. Frøya, 20 August 2021 · Voluntary cash offer to acquire all outstanding shares in Norway Royal Salmon for NOK 270 per share · The Offer values the Company at approximately NOK 11,764 million and represents a 12.5% premium to the NTS offer and a premium of 54.0% to the 30 trading day VWAP of the NRS share prior to the date for the NTS offer · With several overlapping industrial interests, both in Northern Norway, the West Fjords of Iceland, and offshore, a combination offers ample opportunities to

NENT Group restarts Nordic action thriller ‘The Machinery’ for second season

· Kristoffer Joner (‘The Revenant’; ‘Mission: Impossible – Fallout’) reprises starring role in new season · Season one set viewing records on NENT Group’s Viaplay streaming service · NENT Group to premiere at least 50 original productions in 2021 Nordic Entertainment Group (NENT Group) and Norwegian superstar Kristoffer Joner (Hollywood’s ‘The Revenant’; ‘Mission: Impossible – Fallout’) will reunite for a new season of the hit Viaplay Original ‘The Machinery’. The first season of the high-tempo Nordic action thriller series broke viewing records on NENT Group’s Viaplay streaming

P CAPITAL PARTNERS IV ISSUES NEW DEBENTURES

P Capital Partners IV AB (publ) today announces that on 3 September 2021, the company will increase its contributed capital by EUR 15.4 million through the issuance of 154,240 series A1 participation loan debentures at a price of EUR 100 each and by an equity contribution of EUR 0.06 million. The new debentures will be eligible for coupon payments from the fourth quarter 2021. Including the newly issued debentures, P Capital Partners IV’s funding amounts to EUR 166.4 million comprised of series A1 participation loan debentures of EUR 165.8 million and EUR 0.6 million in equity.  P

P CAPITAL PARTNERS IV B ISSUES NEW DEBENTURES

P Capital Partners IV B AB (publ) today announces that on 3 September 2021, the company will increase its contributed capital by EUR 49.1 million through the issuance of 216,400 series A1 and 20,000 series A2 participation loan debentures at a price of EUR 100 each and 25,500 series B participation loan debentures at a price of EUR 1,000 each and by an equity contribution of EUR 0.18 million. The new debentures will be eligible for coupon payments from the fourth quarter 2021. Including the newly issued debentures, P Capital Partners IV B’s funding amounts to EUR 530.2 million

Gradientech: Interim report January 1 - June 30, 2021

Gradientech AB (publ) interim report for Q2 2021 is now available on the company's website www.gradientech.se.Second quarter April-June 2021 · Net sales amounted to 2 KSEK (21 KSEK). · Net loss amounted to SEK -11,516 KSEK (-8,641 KSEK). · Earnings per share were SEK -0.94 (SEK -0.98). · Cashflow from operating activities totalled -10,857 KSEK (-10,389 KSEK). · As of 30 June 2021, cash and cash equivalents totalled 43,995 KSEK (14,297 KSEK). · As of 30 June 2021, equity amounted to 53,668 KSEK (17,340 KSEK). · An external audit (bsi) of the company's ISO13485-

Interim report January-June 2021

Continued strong growth in the second quarter of the year. New acquisition with a strong base and solid establishment in the south of Sweden and a significant increase in net sales, despite continued challenges linked to resource and competence supply in an expansive market.“Like the first quarter of the year, the second quarter has shown solid growth. We welcomed Norrvidinge into the Bellman Group, which has established a strong base for Bellman Group in the south of Sweden. The quarter shows a significant increased Group net sale (SEK 662.2 million), an increase of 45.7 percent compared

TriHealth Good Samaritan Hospital choose WasteLog®

Pharmacolog’s partner, Codonics, to deliver leading Ohio hospital with WasteLog® to assist with drug diversion prevention initiative.Codonics, the exclusive U.S. distributor of WasteLog®, is helping U.S. hospitals reduce the potential threat of drug diversion with WasteLog®, a drug assay device that helps eradicate diversion. The company placed an order for a  WasteLog® system which will be installed at TriHealth Good Samaritan Hospital, the oldest and largest private teaching and tertiary healthcare facility in Greater Cincinnati, Ohio, and part of one of the most integrated healthcare

Greenfood acquires the premium supplier Lundgrens primörer

Greenfood acquires 100 percent of the ownership in fruit and vegetable specialist Lundgrens primörer. A company on Sweden's west coast, Lundgren's has a turnover of almost 90 million SEK. It is known for its wide range consisting of premium fruits, vegetables and processed raw materials of the highest quality."Through the purchase of Lundgren's, we become a nationwide supplier. We are expanding the quality range further and making their fantastic products available to customers and consumers around Sweden," said Ted Stenshed, CEO of the Greenfood Fresh Produce business area. Greenfood

FluoGuide receives tranche of EUR 750,000 under its ongoing grant from EIC Accelerator - SME Instrument under European Union for FG001

Copenhagen, Denmark, 20 August 2021 FluoGuide A/S ("FluoGuide" or the “Company”) is pleased to announce that the Company has received a tranche of EUR 750,000 as pre-financing under the total grant of EUR 2.5 million (approx. DKK 18.6 million or SEK 26.1 million) from the European Innovation Council (EIC) following their twelve-month review of the development of FG001.Last year, the Company announced it was awarded with a grant on in total EUR 2.5 million under the European Innovation Council (EIC) for the purpose of funding both manufacturing (CMC) and clinical work supporting Phase III

Cown Energy AB: Half-year Report January-June 2021

Q2 – april-june 2021 · Revenue amounted to SEK 5,683 thousand (8,247). · Operating loss amounted to SEK -8,461 thousand (24). · Net financial items amounted to SEK 5,925 thousand (19,676). · Unrealised changes in property values amounted to SEK -5,891 thousand (-2,529). · Result before tax amounted to SEK -8,426 thousand (17,171), and result after tax amounted to SEK -8,669 thousand (13,730), corresponding to SEK -0.02 (0.03) per share.  H1 – january-june 2021 · Revenue amounted to SEK 10,562 thousand (17,355). · Operating loss amounted to SEK -11,770 thousand (

Paulig invests in next generation fats for plant-based foods

Paulig’s venture arm PINC has invested in Swedish start-up Melt&Marble, which has developed yeast as a production platform for tasty and sustainable fats for plant-based foods. Melt&Marble has raised EUR 750k in seed funding to finalise its prototype and strengthen the team. Paulig’s product range is almost 100% plant-based, and as a sustainability frontrunner, the company actively seeks innovative products that are good for both people and the planet. Melt&Marble uses precision fermentation to produce sustainable fats for plant-based foods. By engineering the metabolism of yeasts,

INITIATOR PHARMA: INTERIM REPORT JANUARY- JUNE 2021

Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016. Second Quarter (2021-04-01 – 2021-06-30) · Net revenues were TDKK 0 (0) · EBIT was TDKK -4,944 (-3,013) · Earnings per share was DKK –0.14 (-0.13) First Six Months of the Year (2021-01-01 – 2021-06-30) · Net revenues were TDKK 0 (0) · EBIT was TDKK -6,736 (-5,405) · Earnings per share was DKK –0.19 (-0.23) · Cash and bank: TDKK 31,099 (8,189) · Solidity:

ORGANOCLICK AB (PUBL) PUBLISH INTERIM REPORT FOR Q2 2021

"During the second quarter, we recorded our highest quarterly sales ever of a total of SEK 39.8 (36.1) million,which resulted in growth of 10.4 (10.3) %. We also signed agreements with the new customers Stadium, Hööksand XXL Norway for OrganoTex where we continue our expansion. At the end of the quarter, we also deliveredour first bulk delivery of our biobased binders to Duni, which is now preparing its launch of fossil-free napkins."Translation from CEO Mårten Hellbergs comments to the Interim Report.   Q2, 1 April - 30 June 2021 The Group compared with 2020 » Net revenue

Continued Growth and Strengtened Gross Margin Led to Improved Operating Income during the Second Quarter

PowerCell Sweden AB grew its sales by 28 percent during the second quarter 2021, from MSEK 22.2 to MSEK 28.2. Operating income improved to MSEK -21.7 (-28.3) driven by increased sales and strengthened gross margin.In terms of sales, the second quarter 2021 was the strongest second quarter in the company’s history. This was the third quarter in a row with record sales in comparison with corresponding quarters previous years. “Growth was driven by increased demand in all segments while also sales to Robert Bosch remained high. Underlying demand was stronger than what can be seen in the

SRV Group Plc’s financial information in 2022

SRV GROUP PLC     STOCK EXCHANGE RELEASE     20 AUGUST 2021     9.30 EET  SRV Group Plc’s financial information in 2022 SRV Group Plc will publish the following financial information in 2022: · Financial Statement Release 2021 will be published on Thursday, 3 February 2022 at 8.30 am. · Annual Report 2021 (including the Financial Statements and the Report of the Board of Directors) will be published on Wednesday, 2 March 2022. · Interim Report for January-March 2022 will be published on Thursday, 28 April 2022 at 8.30 am. · Half-year Report for January-June 2022 will be

Heliospectra (publ) Half Year Report January-June 2021

(Gothenburg, Sweden August 20th, 2021)– Heliospectra AB (publ (Nasdaq First North Growth Market: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its’ Half Year Report for January-June 2021.Full report is enclosed to this press release and is also uploaded at https://www.heliospectra.com/investor-relations/investor-relations. SUMMARY OF REPORT: Sales And Financial Performance, January–June Order intake during the period April - June amounted to SEK -61,492 thousand. This figure includes the order

SynAct Pharma to present new data on AP1189 for the treatment of rheumatoid arthritis at ACR Convergence 2021

SynAct Pharma AB (“SynAct”) today announced that an abstract entitled ”AP1189: A Novel Oral Biased Melanocortin Agonist with Anti-inflammatory and Pro-resolving Effect for the Treatment of Rheumatoid Arthritis” has been selected for presentation at the ACR Convergence 2021 conference on November 9. AP1189 is a novel oral available compound with anti-inflammatory and pro-resolving effect with the potential to treat active rheumatoid arthritis (RA).SynAct Pharma will present the compound’s topline pharmacology and efficacy data at the event. The compound is currently being tested in a double-

Fossil free energy from Vattenfall enables reduced emissions in Orthex´s production

Vattenfall delivers 100 percent fossil free hydro power to Orthex´s factories in Sweden and Finland. This is an important part in Orthex´s ongoing sustainability work and goal to be carbon neutral in production by 2030.Last year, Vattenfall and Orthex Corporation, a leading Nordic producer of household products, signed an electricity supply agreement of 100 percent electricity from hydro power labelled EPD (Environmental Product Declaration) to the factory in Lohja, Finland. As of 2021 Vattenfall also delivers 100 percent electricity from hydro power labelled EPD to Orthex´s factories in

Fossil free energy from Vattenfall enables reduced emissions in Orthex’s production

Orthex Corporation, Press release, August 20, 2021 at 9.15 a.m. EEST Vattenfall delivers 100 percent fossil free hydro power to Orthex’s factories in Sweden and Finland. This is an important part in Orthex´s ongoing sustainability work and goal to be carbon neutral in production by 2030.Last year, Vattenfall and Orthex Corporation, a leading Nordic producer of household products, signed an electricity supply agreement of 100 percent electricity from hydro power labelled EPD (Environmental Product Declaration) to the factory in Lohja, Finland. As of 2021 Vattenfall also delivers 100

poLight ASA – purchase order received for mass production preparation for a surgical device

Horten, 20 August 2021 - poLight ASA (OSE: PLT) today announced that the company has received a purchase order for TLens, including a custom assembly service, in preparation for mass production of an ultra-compact surgical device under development by a medical customer worth NOK 2.300.000. “This purchase order gives us an exciting opportunity to expand into the medical market segment for the first time. Our customer’s surgical device that uses our TLens AF enabled camera is still under development and changes may happen, but as of now we are designed in and our customer’s initial

Update on Ultomiris Phase III ALS trial

20 August 2021 07:05 BST Update on CHAMPION-ALS Phase III trial of Ultomiris in amyotrophic lateral sclerosis     Alexion is discontinuing CHAMPION-ALS, the global Phase III clinical trial of Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis (ALS).   This decision is based on the recommendation of the Independent Data Monitoring Committee (IDMC), following their review of data from a pre-specified interim analysis. The IDMC recommended that the trial be discontinued due to lack of efficacy. No new safety findings were observed and the data were

There are no items matching the current filter
There are no more items matching the current filter
Back to top